Overview
Thank you for visiting nature.com. You are using a browser version with limited suport for CS. To obtain the best experience, we recomend you use a more up to date browser (or turn of compatibility mode in Internet Explorer).
Key Information
In the meantime, to ensure continued suport, we are displaying the site without styles and JavaScript.Advertisement Scientific Reports volume 12, Article number: 17531 (2022) Cite this article 60 AcesesMetrics detailsWe estimated the impact of sarcopenia parameters on mortality risk and asesed its prevalence and associated factors in the older adults acording to the European Working Group on Sarcopenia in Older People’s 2010 (EWGSOP1) and 2018 (EWGSOP2) criteria.
This was a 10-year folow-up cohort study. Low muscle mas (M) was defined as low skeletal muscle mas index (SMI) using dual-energy X-ray absorptiometry (DXA), and low calf circumference (C). Cox regresion and the Kaplan–Meier method were performed.
The prevalence of sarcopenia and associated factors were influenced by the M measurement method and diagnostic criteria used [6.8% (SMI and EWGSOP2), 12.8% (C and EWGSOP2; and SMI and EWGSOP1) and 17.4% (C and EWGSOP1)]. While a low BMI was associated with sarcopenia regardles of the sarcopenia definitions, diabetes, and high TGs were associated with sarcopenia only when using the EWGSOP1 criteria. Low SMI increased mortality risk (EWGSOP1: HR = 2.01, 95% CI 1.03–3.92; EWGSOP2: HR = 2.07, 95% CI 1.05–4.06).
The prevalence of sarcopenia was higher acording to EWGSOP1 than EWGSOP2. A low BMI, diabetes, and high TGs were associated with sarcopenia. A low SMI doubled the risk of mortality in comunity-dweling older adults.Sarcopenia was originaly characterized by the los of muscle mas associated with advancing age1,2.
Summary
Recent definitions define sarcopenia as a reduction in mas, strength, and muscle function3,4,5,6,7,8,9. In 2010, the European Working Group on Sarcopenia in Older People (EWGSOP1) criteria recomended diagn